Participant flow

Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy · Source last updated 2023-07-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   F-627, 20 mg fixed dose pre-filled syringe, administered on Day 2 of each of 4 chemotherapy cycles. F-627: single dose pre-filled syringe

   id

   FG000

   title

   F-627

2. description

   6 mg fixed dose Neulasta®, administered on Day 2 of each of 4 chemotherapy cycles Neulasta: single dose pre-filled syringe

   id

   FG001

   title

   Neulasta

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         197

      2. group Id

         FG001

         num Subjects

         196

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         186

      2. group Id

         FG001

         num Subjects

         187

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         11

      2. group Id

         FG001

         num Subjects

         9

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice